NIN: A Potential Drug Target for Neurological Conditions (G51199)

Target Name: NIN

NCBI ID: G51199

Content of Review Report on NIN Target / Biomarker

NIN

NIN: A Potential Drug Target for Neurological Conditions

NIN (Ninein) is a protein that is expressed in the brain and has been shown to play a role in various neurological conditions, including Alzheimer's disease, Parkinson's disease, and neurodegenerative disorders. It is also known as the N-methyl-D-aspartate (NMDA) receptor ligand, a protein that is involved in the regulation of neural signaling.

Recent studies have suggested that NIN may be a drug target or biomarker for various neurological conditions, including Alzheimer's disease, Parkinson's disease, and neurodegenerative disorders.

One of the main reasons for the interest in NIN is its role in the regulation of neural signaling. Neural signaling is the process by which neurons communicate with each other and with the brain. NIN is involved in the regulation of this process, and its absence or dysfunction has been implicated in the development of various neurological conditions.

One of the key functions of NIN is its role in the regulation of synaptic plasticity, which is the ability of the brain to change and adapt in response to experience. Studies have shown that NIN plays a key role in the regulation of synaptic plasticity, and Its dysfunction has been implicated in the development of Alzheimer's disease and other neurological conditions.

Another function of NIN is its role in the regulation of neuroinflammation, which is the inflammation that occurs in the brain in response to the presence of foreign particles or pathogens. Studies have shown that NIN plays a key role in the regulation of neuroinflammation, and its Dysfunction has been implicated in the development of various neurological conditions.

In addition to its role in the regulation of neural signaling and neuroinflammation, NIN is also involved in the regulation of cell survival. Studies have shown that NIN plays a key role in the regulation of cell survival, and its dysfunction has been implicated in the development of various neurological conditions.

Given its involvement in the regulation of neural signaling, neuroinflammation, and cell survival, NIN is a promising drug target or biomarker for a variety of neurological conditions. Studies are currently being conducted to determine the effectiveness of NIN as a drug treatment or biomarker for various neurological conditions, including Alzheimer's disease, Parkinson's disease, and neurodegenerative disorders.

In conclusion, NIN is a protein that is expressed in the brain and is involved in the regulation of various neurological conditions, including Alzheimer's disease, Parkinson's disease, and neurodegenerative disorders. Its role in the regulation of neural signaling, neuroinflammation, and cell survival makes it a promising drug target or biomarker for a variety of neurological conditions. Further studies are needed to determine the effectiveness of NIN as a drug treatment or biomarker for these conditions.

Protein Name: Ninein

Functions: Centrosomal protein required in the positioning and anchorage of the microtubule minus-end in epithelial cells (PubMed:15190203, PubMed:23386061). May also act as a centrosome maturation factor (PubMed:11956314). May play a role in microtubule nucleation, by recruiting the gamma-tubulin ring complex to the centrosome (PubMed:15190203). Overexpression does not perturb nucleation or elongation of microtubules but suppresses release of microtubules (PubMed:15190203). Required for centriole organization and microtubule anchoring at the mother centriole (PubMed:23386061)

The "NIN Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NIN comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets